{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:39:11Z","timestamp":1793691551903,"version":"4.5.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Osteoarthritis (OA) is a widespread degenerative joint disorder manifesting as chronic pain, functional impairment, and progressive disability, imposing a substantial burden on global public health. Despite extensive research, the precise molecular pathways underlying OA pathogenesis remain incompletely elucidated. Our data indicated that human OA cartilage and cartilaginous tissues from aged mice exhibited markedly elevated levels of extracellular signal-related kinase 5 (ERK5) enzyme activity. Using\n                    <jats:italic>Col2a1-CreER<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>T2<\/jats:italic>\n                    <\/jats:sup>\n                    \/\n                    <jats:italic>Erk5<\/jats:italic>\n                    <jats:sup>flox\/flox<\/jats:sup>\n                    mice, we found that\n                    <jats:italic>Erk5<\/jats:italic>\n                    deletion in cartilage inhibited the progression of post-traumatic and aging OA mouse while constitutive activation of ERK5 significantly accelerated OA development via intra-articular injection of adeno-associated virus model. Mechanistically, ERK5 interacted with the PYD domain of NLRP3 and mediated NLRP3 phosphorylation at serine 198, which facilitated mature inflammasome assembly, triggered pyroptosis and subsequently exacerbated OA progression. Furthermore, we identified a small compound, Oroxylin A, which attenuated ERK5 activation and effectively ameliorated the development of post-traumatic and aging-induced OA in mice. Taken together, our studies demonstrate that ERK5 is a key regulator effecting chondrocytes inflammation and pyroptosis through activating NLRP3 inflammasome and ERK5 is a potential therapeutic target for OA treatment.\n                  <\/jats:p>","DOI":"10.1038\/s41413-026-00573-x","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:36:51Z","timestamp":1788341811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inhibition of ERK5 activity ameliorates osteoarthritis by suppressing NLRP3 inflammasome-mediated chondrocyte pyroptosis"],"prefix":"10.1038","volume":"14","author":[{"given":"Baolin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deying","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricong","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingtong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuanHong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taifeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiqiang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"573_CR1","doi-asserted-by":"crossref","unstructured":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 5, e508\u2013e522 (2023).","DOI":"10.1016\/S2665-9913(23)00163-7"},{"key":"573_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41572-025-00594-6","volume":"11","author":"S Tang","year":"2025","unstructured":"Tang, S. et al. Osteoarthritis. Nat. Rev. Dis. Prim. 11, 10 (2025).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"573_CR3","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/S0140-6736(18)31064-X","volume":"391","author":"R Barnett","year":"2018","unstructured":"Barnett, R. Osteoarthritis. Lancet 391, 1985 (2018).","journal-title":"Lancet"},{"key":"573_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","volume":"8","author":"Q Yao","year":"2023","unstructured":"Yao, Q. et al. Osteoarthritis: pathogenic signaling pathways and therapeutic targets. Signal Transduct. Target. Ther. 8, 56 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"573_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/art.41142","volume":"72","author":"SL Kolasinski","year":"2020","unstructured":"Kolasinski, S. L. et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the Management of Osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 72, 220\u2013233 (2020).","journal-title":"Arthritis Rheumatol."},{"key":"573_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMcp1903768","volume":"384","author":"L Sharma","year":"2021","unstructured":"Sharma, L. Osteoarthritis of the Knee. N. Engl. J. Med. 384, 51\u201359 (2021).","journal-title":"N. Engl. J. Med."},{"key":"573_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03367-2","volume":"21","author":"JB Driban","year":"2020","unstructured":"Driban, J. B. et al. Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review. BMC Musculoskelet. Disord. 21, 332 (2020).","journal-title":"BMC Musculoskelet. Disord."},{"key":"573_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s12016-022-08941-1","volume":"64","author":"F Motta","year":"2023","unstructured":"Motta, F., Barone, E., Sica, A. & Selmi, C. Inflammaging and osteoarthritis. Clin. Rev. allergy Immunol. 64, 222\u2013238 (2023).","journal-title":"Clin. Rev. allergy Immunol."},{"key":"573_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/jama.2020.22171","volume":"325","author":"JN Katz","year":"2021","unstructured":"Katz, J. N., Arant, K. R. & Loeser, R. F. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA 325, 568\u2013578 (2021).","journal-title":"JAMA"},{"key":"573_CR10","doi-asserted-by":"publisher","first-page":"8382","DOI":"10.1128\/MCB.20.22.8382-8389.2000","volume":"20","author":"HG Kasler","year":"2000","unstructured":"Kasler, H. G., Victoria, J., Duramad, O. & Winoto, A. ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain. Mol. Cell. Biol. 20, 8382\u20138389 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"573_CR11","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/sj.embor.7400755","volume":"7","author":"S Nishimoto","year":"2006","unstructured":"Nishimoto, S. & Nishida, E. MAPK signalling: ERK5 versus ERK1\/2. EMBO Rep. 7, 782\u2013786 (2006).","journal-title":"EMBO Rep."},{"key":"573_CR12","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.cellsig.2012.07.007","volume":"24","author":"GN Nithianandarajah-Jones","year":"2012","unstructured":"Nithianandarajah-Jones, G. N., Wilm, B., Goldring, C. E. P., M\u00fcller, J. & Cross, M. J. ERK5: structure, regulation and function. Cell. Signal. 24, 2187\u20132196 (2012).","journal-title":"Cell. Signal."},{"key":"573_CR13","doi-asserted-by":"crossref","unstructured":"Paudel, R., Fusi, L. & Schmidt, M. The MEK5\/ERK5 pathway in health and disease. Int. J. Mol. Sci. 22, 7594 (2021).","DOI":"10.3390\/ijms22147594"},{"key":"573_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jhep.2007.08.010","volume":"48","author":"E Rovida","year":"2008","unstructured":"Rovida, E., Navari, N., Caligiuri, A., Dello Sbarba, P. & Marra, F. ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J. Hepatol. 48, 107\u2013115 (2008).","journal-title":"J. Hepatol."},{"key":"573_CR15","doi-asserted-by":"publisher","first-page":"e1718","DOI":"10.1038\/cddis.2015.83","volume":"6","author":"AES Sim\u00f5es","year":"2015","unstructured":"Sim\u00f5es, A. E. S. et al. Aberrant MEK5\/ERK5 signalling contributes to human colon cancer progression via NF-\u03baB activation. Cell Death Dis. 6, e1718 (2015).","journal-title":"Cell Death Dis."},{"key":"573_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.devcel.2010.12.005","volume":"20","author":"K Sunadome","year":"2011","unstructured":"Sunadome, K. et al. ERK5 regulates muscle cell fusion through Klf transcription factors. Dev. Cell 20, 192\u2013205 (2011).","journal-title":"Dev. Cell"},{"key":"573_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2005.11.003","volume":"18","author":"X Wang","year":"2006","unstructured":"Wang, X. & Tournier, C. Regulation of cellular functions by the ERK5 signalling pathway. Cell. Signal. 18, 753\u2013760 (2006).","journal-title":"Cell. Signal."},{"key":"573_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/jcp.22120","volume":"224","author":"BE Bobick","year":"2010","unstructured":"Bobick, B. E., Matsche, A. I., Chen, F. H. & Tuan, R. S. The ERK5 and ERK1\/2 signaling pathways play opposing regulatory roles during chondrogenesis of adult human bone marrow-derived multipotent progenitor cells. J. Cell Physiol. 224, 178\u2013186 (2010).","journal-title":"J. Cell Physiol."},{"key":"573_CR19","doi-asserted-by":"crossref","unstructured":"Iezaki, T. et al. The MAPK Erk5 is necessary for proper skeletogenesis involving a Smurf-Smad-Sox9 molecular axis. Development 145, dev164004 (2018).","DOI":"10.1242\/dev.164004"},{"key":"573_CR20","first-page":"1","volume":"62","author":"C Wang","year":"2016","unstructured":"Wang, C. et al. Sox9-induced chondrogenesis in mesenchymal stem cells was mediated by ERK5 signal pathway. Cell. Mol. Biol. 62, 1\u20137 (2016).","journal-title":"Cell. Mol. Biol."},{"key":"573_CR21","doi-asserted-by":"publisher","first-page":"ra86","DOI":"10.1126\/scisignal.aaa3206","volume":"8","author":"K Wilhelmsen","year":"2015","unstructured":"Wilhelmsen, K. et al. Extracellular signal-regulated kinase 5 promotes acute cellular and systemic inflammation. Sci. Signal. 8, ra86 (2015).","journal-title":"Sci. Signal."},{"key":"573_CR22","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/0008-5472.CAN-13-3043","volume":"75","author":"KG Finegan","year":"2015","unstructured":"Finegan, K. G. et al. ERK5 is a critical mediator of inflammation-driven cancer. Cancer Res. 75, 742\u2013753 (2015).","journal-title":"Cancer Res."},{"key":"573_CR23","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202300323R","volume":"37","author":"I Seidita","year":"2023","unstructured":"Seidita, I. et al. Sphingosine 1-phosphate elicits a ROS-mediated proinflammatory response in human endometrial stromal cells via ERK5 activation. FASEB J. 37, e23061 (2023).","journal-title":"FASEB J."},{"key":"573_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.120","volume":"3","author":"Y Ding","year":"2022","unstructured":"Ding, Y. et al. Tyrosine phosphatase SHP2 exacerbates psoriasis-like skin inflammation in mice via ERK5-dependent NETosis. MedComm 3, e120 (2022).","journal-title":"MedComm"},{"key":"573_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.732630","volume":"12","author":"SJ Howell","year":"2021","unstructured":"Howell, S. J. et al. Retinal inflammation, oxidative stress, and vascular impairment is ablated in diabetic mice receiving XMD8-92 treatment. Front. Pharmacol. 12, 732630 (2021).","journal-title":"Front. Pharmacol."},{"key":"573_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13578-020-00462-8","volume":"10","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Conditional ablation of MAPK7 expression in chondrocytes impairs endochondral bone formation in limbs and adaptation of chondrocytes to hypoxia. Cell Biosci. 10, 103 (2020).","journal-title":"Cell Biosci."},{"key":"573_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2024.110053","volume":"36","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Targeting TRPA1 with liposome-encapsulated drugs anchored to microspheres for effective osteoarthritis treatment. Chin. Chem. Lett. 36, 110053 (2025).","journal-title":"Chin. Chem. Lett."},{"key":"573_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41565-025-02082-0","volume":"21","author":"X Chen","year":"2026","unstructured":"Chen, X. et al. Viral glycoprotein-mimicking peptide-functionalized micelles promote drug delivery to diseased chondrocytes for osteoarthritis alleviation. Nat. Nanotechnol. 21, 300\u2013310 (2026).","journal-title":"Nat. Nanotechnol."},{"key":"573_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/srep45006","volume":"7","author":"G Wang","year":"2017","unstructured":"Wang, G. et al. Resveratrol mitigates lipopolysaccharide-mediated acute inflammation in rats by inhibiting the TLR4\/NF-\u03baBp65\/MAPKs signaling cascade. Sci. Rep. 7, 45006 (2017).","journal-title":"Sci. Rep."},{"key":"573_CR30","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/j.1471-4159.2007.04698.x","volume":"102","author":"H Katsura","year":"2007","unstructured":"Katsura, H. et al. Activation of extracellular signal-regulated protein kinases 5 in primary afferent neurons contributes to heat and cold hyperalgesia after inflammation. J. Neurochem. 102, 1614\u20131624 (2007).","journal-title":"J. Neurochem."},{"key":"573_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s11658-023-00462-9","volume":"28","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. The NLRP3 inflammasome: contributions to inflammation-related diseases. Cell. Mol. Biol. Lett. 28, 51 (2023).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"573_CR32","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/art.42505","volume":"75","author":"T Ebata","year":"2023","unstructured":"Ebata, T. et al. Noncanonical pyroptosis triggered by macrophage-derived extracellular vesicles in chondrocytes leading to cartilage catabolism in osteoarthritis. Arthritis Rheumatol. 75, 1358\u20131369 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"573_CR33","first-page":"47","volume":"44","author":"H Tang","year":"2024","unstructured":"Tang, H. et al. The IRF1\/GBP5 axis promotes osteoarthritis progression by activating chondrocyte pyroptosis. J. Orthop. Transl. 44, 47\u201359 (2024).","journal-title":"J. Orthop. Transl."},{"key":"573_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cytogfr.2020.08.003","volume":"55","author":"A Gritsenko","year":"2020","unstructured":"Gritsenko, A., Green, J. P., Brough, D. & Lopez-Castejon, G. Mechanisms of NLRP3 priming in inflammaging and age related diseases. Cytokine Growth Factor Rev. 55, 15\u201325 (2020).","journal-title":"Cytokine Growth Factor Rev."},{"key":"573_CR35","first-page":"1793","volume":"130","author":"L Mao","year":"2020","unstructured":"Mao, L. et al. Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1\u03b2-mediated colitis. J. Clin. Invest. 130, 1793\u20131807 (2020).","journal-title":"J. Clin."},{"key":"573_CR36","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1111\/jcmm.17438","volume":"26","author":"H Bai","year":"2022","unstructured":"Bai, H. et al. Activation of adenosine A3 receptor attenuates progression of osteoarthritis through inhibiting the NLRP3\/caspase-1\/GSDMD induced signalling. J. Cell. Mol. Med. 26, 4230\u20134243 (2022).","journal-title":"J. Cell. Mol. Med."},{"key":"573_CR37","doi-asserted-by":"crossref","unstructured":"Ma, J. et al. GYY4137-induced p65 sulfhydration protects synovial macrophages against pyroptosis by improving mitochondrial function in osteoarthritis development. J. Adv. Res. 71, 173\u2013188 (2024).","DOI":"10.1016\/j.jare.2024.05.033"},{"key":"573_CR38","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/ni.3538","volume":"17","author":"L Mortimer","year":"2016","unstructured":"Mortimer, L., Moreau, F., MacDonald, J. A. & Chadee, K. NLRP3 inflammasome inhibition is disrupted in a group of auto-inflammatory disease CAPS mutations. Nat. Immunol. 17, 1176\u20131186 (2016).","journal-title":"Nat. Immunol."},{"key":"573_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P.-Y. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"573_CR40","doi-asserted-by":"crossref","unstructured":"Bittner Z. A. et al. BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. J. Exp. Med. 218, e20201656 (2021).","DOI":"10.1084\/jem.20201656"},{"key":"573_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8360","volume":"6","author":"M Ito","year":"2015","unstructured":"Ito, M. et al. Bruton\u2019s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat. Commun. 6, 7360 (2015).","journal-title":"Nat. Commun."},{"key":"573_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26142-w","volume":"12","author":"T Niu","year":"2021","unstructured":"Niu, T. et al. NLRP3 phosphorylation in its LRR domain critically regulates inflammasome assembly. Nat. Commun. 12, 5862 (2021).","journal-title":"Nat. Commun."},{"key":"573_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12868","volume":"53","author":"H Pan","year":"2020","unstructured":"Pan, H. et al. Wedelolactone facilitates Ser\/Thr phosphorylation of NLRP3 dependent on PKA signalling to block inflammasome activation and pyroptosis. Cell Prolif. 53, e12868 (2020).","journal-title":"Cell Prolif."},{"key":"573_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202350382","volume":"53","author":"Y Qin","year":"2023","unstructured":"Qin, Y. & Zhao, W. Posttranslational modifications of NLRP3 and their regulatory roles in inflammasome activation. Eur. J. Immunol. 53, e2350382 (2023).","journal-title":"Eur. J. Immunol."},{"key":"573_CR45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.abb.2019.02.020","volume":"670","author":"CF Sandall","year":"2019","unstructured":"Sandall, C. F. & MacDonald, J. A. Effects of phosphorylation on the NLRP3 inflammasome. Arch. Biochem. Biophys. 670, 43\u201357 (2019).","journal-title":"Arch. Biochem. Biophys."},{"key":"573_CR46","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.3389\/fimmu.2018.02305","volume":"9","author":"N Song","year":"2018","unstructured":"Song, N. & Li, T. Regulation of NLRP3 inflammasome by phosphorylation. Front. Immunol. 9, 2305 (2018).","journal-title":"Front. Immunol."},{"key":"573_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molcel.2017.08.017","volume":"68","author":"N Song","year":"2017","unstructured":"Song, N. et al. NLRP3 phosphorylation is an essential priming event for inflammasome activation. Mol. cell 68, 185\u2013197.e6 (2017).","journal-title":"Mol. cell"},{"key":"573_CR48","first-page":"1783","volume":"126","author":"MR Spalinger","year":"2016","unstructured":"Spalinger, M. R. et al. NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase PTPN22. J. Clin. Invest. 126, 1783\u20131800 (2016).","journal-title":"J. Clin."},{"key":"573_CR49","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201949666","volume":"21","author":"A Zhang","year":"2020","unstructured":"Zhang, A. et al. EphA2 phosphorylates NLRP3 and inhibits inflammasomes in airway epithelial cells. EMBO Rep. 21, e49666 (2020).","journal-title":"EMBO Rep."},{"key":"573_CR50","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.4049\/jimmunol.2000649","volume":"205","author":"W Zhao","year":"2020","unstructured":"Zhao, W. et al. AKT regulates NLRP3 inflammasome activation by phosphorylating NLRP3 serine 5. J. Immunol. 205, 2255\u20132264 (2020).","journal-title":"J. Immunol."},{"key":"573_CR51","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1038\/s41423-021-00761-1","volume":"18","author":"K Zhu","year":"2021","unstructured":"Zhu, K. et al. Priming of NLRP3 inflammasome activation by Msn kinase MINK1 in macrophages. Cell. Mol. Immunol. 18, 2372\u20132382 (2021).","journal-title":"Cell. Mol. Immunol."},{"key":"573_CR52","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/s41385-020-0307-5","volume":"13","author":"C Zhang","year":"2020","unstructured":"Zhang, C. et al. ADP\/P2Y(1) aggravates inflammatory bowel disease through ERK5-mediated NLRP3 inflammasome activation. Mucosal Immunol. 13, 931\u2013945 (2020).","journal-title":"Mucosal Immunol."},{"key":"573_CR53","doi-asserted-by":"crossref","unstructured":"Sajeev, A. et al. Oroxylin A: a promising flavonoid for prevention and treatment of chronic diseases. Biomolecules 12, 1185 (2022).","DOI":"10.3390\/biom12091185"},{"key":"573_CR54","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1111\/bph.17349","volume":"181","author":"Y Ma","year":"2024","unstructured":"Ma, Y. et al. Oroxylin A attenuates psoriasiform skin inflammation by direct targeting p62 (sequestosome 1) via suppressing M1 macrophage polarization. Br. J. Pharmacol. 181, 5110\u20135132 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"573_CR55","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1039\/D0FO02159H","volume":"12","author":"D-H Chen","year":"2021","unstructured":"Chen, D.-H. et al. Oroxylin A attenuates osteoarthritis progression by dual inhibition of cell inflammation and hypertrophy. Food Funct. 12, 328\u2013339 (2021).","journal-title":"Food Funct."},{"key":"573_CR56","doi-asserted-by":"crossref","unstructured":"Zhang, H. et al. Maintaining hypoxia environment of subchondral bone alleviates osteoarthritis progression. Sci. Adv. 9, eabo7868 (2023).","DOI":"10.1126\/sciadv.abo7868"},{"key":"573_CR57","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3892\/etm.2021.9819","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Weng, Q., Chen, J., Li, M. & Han, J. Oroxylin A attenuates IL-1\u03b2-induced inflammatory reaction via inhibiting the activation of the ERK and PI3K\/AKT signaling pathways in osteoarthritis chondrocytes. Exp. Ther. Med. 21, 388 (2021).","journal-title":"Exp. Ther. Med."},{"key":"573_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adq1735","volume":"17","author":"Z Li","year":"2025","unstructured":"Li, Z. et al. TRIM15 drives chondrocyte senescence and osteoarthritis progression. Sci. Transl. Med. 17, eadq1735 (2025).","journal-title":"Sci. Transl. Med."},{"key":"573_CR59","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.41988","volume":"74","author":"Q Liu","year":"2022","unstructured":"Liu, Q. et al. SH2 domain-containing phosphatase 2 inhibition attenuates osteoarthritis by maintaining homeostasis of cartilage metabolism via the docking protein 1\/uridine phosphorylase 1\/uridine cascade. Arthritis Rheumatol. 74, 462\u2013474 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"573_CR60","volume":"136","author":"B Zhang","year":"2025","unstructured":"Zhang, B. et al. M13, an anthraquinone compound isolated from Morinda officinalis alleviates the progression of the osteoarthritis via the regulation of STAT3. Phytomed. Int. J. Phytother. Phytopharmacol. 136, 156329 (2025).","journal-title":"Phytomed. Int. J. Phytother. Phytopharmacol."},{"key":"573_CR61","doi-asserted-by":"publisher","DOI":"10.1063\/5.0018516","volume":"153","author":"S P\u00e1ll","year":"2020","unstructured":"P\u00e1ll, S. et al. Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS. J. Chem. Phys. 153, 134110 (2020).","journal-title":"J. Chem. Phys."},{"key":"573_CR62","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","volume":"26","author":"D van der Spoel","year":"2005","unstructured":"van der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701\u20131718 (2005).","journal-title":"J. Comput. Chem."}],"container-title":["Bone Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00573-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00573-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:04:30Z","timestamp":1790089470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41413-026-00573-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1038\/s41413-026-00573-x","relation":{},"ISSN":["2095-6231"],"issn-type":[{"value":"2095-6231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Acknowledgements section has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"95"}}